tiprankstipranks
Lexicon announces analyses of results from SOLOIST-WHF Phase 3 outcomes study
The Fly

Lexicon announces analyses of results from SOLOIST-WHF Phase 3 outcomes study

Lexicon Pharmaceuticals announced new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational product sotagliflozin presented at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology in New Orleans, Louisiana. The "Time to Clinical Benefit of Sotagliflozin in People with Worsening Heart Failure in SOLOIST-WHF" post hoc analysis examined the timing of clinical benefit of sotagliflozin, defined as the first day post randomization when the hazard ratio for risk for the primary outcome of total number of cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure was statistically significant and remained significant throughout follow up. A subgroup analysis was also conducted in patients with left ventricular ejection fraction less than 50% or greater than or equal to 50%. The analysis showed a statistically significant reduction in the risk for the primary outcome on Day 27, or time to clinical benefit of 27 days, in patients with worsening heart failure treated with sotagliflozin. Furthermore, these findings were generally consistent across the LVEF range. As previously reported, in patients admitted with WHF, sotagliflozin significantly reduced the composite of total cardiovascular death, hospitalization for heart failure, and urgent visit for heart failure by 33%.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on LXRX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles